Kinevant Sciences is a clinical-stage biopharmaceutical company. Their lead investigational product candidate is namilumab, which is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor (GM-CSF), a key pro-inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.
Location: United States, New York
Employees: 11-50